Dr. Darin B. Brimhall

Internal Medicine
8285 W Arby Ave, Ste 331, 
Las Vegas, NV 
Accepting New Patients
8285 W Arby Ave, Ste 331, 
Las Vegas, NV 

Overview

Darin Brimhall is a primary care provider, practicing in Internal Medicine in Las Vegas, Nevada.

Dr. Brimhall is board certified in Internal Medicine. He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 8 clinical trials. Dr. Brimhall is currently accepting new patients.

Graduate Institution

College Of Osteopathic Medicine & Surgery

Specialties

Internal Medicine

Licenses

Internal Medicine in NV

Board Certifications

Internal Medicine

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Darin B. Brimhall, DO Private Practice
8285 W Arby Ave, Ste 331, Las Vegas, NV 89113

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Subjects Compared With Matched, Healthy, Non-Hispanic, Caucasian Subjects and to Assess Dose-Proportionality of 3 Doses of Maribavir in the Japanese Subjects
A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Subjects Compared With Matched, Healthy, Non-Hispanic, Caucasian Subjects and to Assess Dose-Proportionality of 3 Doses of Maribavir in the Japanese Subjects
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4004280 in Healthy Participants
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Administered VH4011499 in Healthy Participants
Enrollment Status: Completed
Publish Date: April 01, 2025
Intervention Type: Drug
Study Phase: Phase 1
Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects
Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants
A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Drug
Study Drug: Cabotegravir Sodium
Study Phase: Phase 1
A Pharmacokinetic, Multi-cohort Study in Healthy Adult Subjects to Assess Gepotidacin as Victim and as Perpetrator of Drug-Drug Interactions Via CYP450, Renal and Intestinal Transporters, and to Assess Gepotidacin Pharmacokinetics in Japanese Healthy Adults
A Pharmacokinetic, Multi-cohort Study in Healthy Adult Subjects to Assess Gepotidacin as Victim and as Perpetrator of Drug-Drug Interactions Via CYP450, Renal and Intestinal Transporters, and to Assess Gepotidacin Pharmacokinetics in Japanese Healthy Adults
Enrollment Status: Completed
Publish Date: March 04, 2022
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants
A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

12 Total Publications

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.
Journal: Clinical pharmacology in drug development
Published: January 16, 2025
Similar Doctors
Expertise in
22
conditions
Dr. George Baramidze
Internal Medicine
Expertise in
22
conditions
Dr. George Baramidze
Internal Medicine

Nevada Nephrology Consultants

2820 W Charleston Blvd, Ste 33, 
Las Vegas, NV 
 (5.6 miles away)
702-880-1558
Languages Spoken:
English
See accepted insurances
Accepting New Patients

George Baramidze is an Internal Medicine provider practicing medicine in Las Vegas, Nevada. Dr. Baramidze is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Acute Kidney Failure, Necrosis, End-Stage Renal Disease (ESRD), and Low Sodium Level. Dr. Baramidze is board certified in Internal Medicine (Sub: Nephrology). Dr. Baramidze is currently accepting new patients.

Expertise in
15
conditions
Dr. Gary Grossman
Internal Medicine
Expertise in
15
conditions
Dr. Gary Grossman
Internal Medicine

Internal Medicine Spec. Of Southern NV Grossman Panikkar Ghadishah Whi

201 N Buffalo Dr, 
Las Vegas, NV 
 (10.1 miles away)
702-242-2737
Languages Spoken:
English
See accepted insurances

Gary Grossman is a primary care provider, practicing in Internal Medicine in Las Vegas, Nevada. Dr. Grossman is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Homozygous Familial Hypercholesterolemia (HoFH), Defective Apolipoprotein B-100, Heterozygous Familial Hypercholesterolemia (HeFH), and Familial Hypercholesterolemia.

Expertise in
9
conditions
Dr. Rebecca Sinai
Internal Medicine
Expertise in
9
conditions
Dr. Rebecca Sinai
Internal Medicine

Internal Medicine Spec. Of Southern NV Grossman Panikkar Ghadishah Whi

201 N Buffalo Dr, 
Las Vegas, NV 
 (10.1 miles away)
702-242-2737
Languages Spoken:
English
See accepted insurances

Rebecca Sinai is a primary care provider, practicing in Internal Medicine in Las Vegas, Nevada. Dr. Sinai is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Olivopontocerebellar Atrophy, Primary Familial Brain Calcification, Cerebelloolivary Atrophy, Vitamin D Deficiency, and Myringotomy.

Frequently Asked Questions about Dr. Darin B. Brimhall

How do I make an appointment with Dr. Darin B. Brimhall?

You can book an appointment with Dr. Darin B. Brimhall by calling their office at 702-963-1598. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Does Dr. Darin B. Brimhall accept my insurance?

Dr. Darin B. Brimhall accepts most major insurance plans, including Cigna and Louisiana Healthcare Connections. We recommend calling the office directly at 702-963-1598 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brimhall's expertise for a condition
ConditionClose

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile